Emerging treatment strategies for HER2-mutant NSCLC: Striving for selectivity, efficacy, and tolerability

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Human epidermal growth factor receptor 2 (HER2) is a validated drug target in various cancers.
• HER2 mutations occur in 1.8-5.6% of non-small cell lung cancer (NSCLC) tumors, representing a significant unmet need.
• Existing HER2-directed therapies are limited in NSCLC, unlike in breast and gastric cancers.

Purpose of the Study:

• To review the current landscape of HER2-directed treatment options for NSCLC.
• To summarize the development and efficacy of novel therapeutic agents targeting HER2-mutant NSCLC.
• To highlight the unmet need and future directions in HER2-mutant NSCLC treatment.

Main Methods:

• Literature review of clinical trials and studies on HER2-mutant NSCLC.
• Analysis of data on approved and investigational HER2-directed therapies.
• Synthesis of information on antibody-drug conjugates and tyrosine kinase inhibitors.

Main Results:

• Trastuzumab deruxtecan is a key HER2-targeting antibody-drug conjugate.
• Tyrosine kinase inhibitors are emerging as a promising therapeutic class.
• Limited first-line HER2-directed options currently exist for NSCLC.

Conclusions:

• HER2-mutant NSCLC requires novel therapeutic strategies.
• Antibody-drug conjugates and tyrosine kinase inhibitors show potential for improving patient outcomes.
• Further research and clinical development are crucial for addressing this specific patient population.